Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 5, 2014, Pages 747-755

  Cathcart, Mary Clare ^a   Gately, Kathy ^a   Cummins, Robert ^b   Drakeford, Clive ^a   W Kay, Elaine ^b   O'Byrne, Kenneth J ^a,c   Pidgeon, Graham P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Angiogenesis; CD 31; Non small cell lung cancer; Thromboxane synthase; VEGF

Indexed keywords

CD31 ANTIGEN; THROMBOXANE B2; THROMBOXANE SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL SURVIVAL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANGIOGENESIS; CD-31; NON-SMALL CELL LUNG CANCER; THROMBOXANE SYNTHASE; VEGF;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOXANE B2; THROMBOXANE-A SYNTHASE; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895751725     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.011     Document Type: Article

References (60)

1. Alberg A.J., Brock M.V., Samet J.M. Epidemiology of lung cancer: looking to the future. J. Clin. Oncol. 2005, 23:3175-3185.
2. Spicer J., Chowdhury S., Harper P. Targeting novel and established therapies for non-small cell lung cancer. Cancer Lett. 2007, 250:9-16.
3. Carney D.N. Lung cancer-time to move on from chemotherapy. N. Engl. J. Med. 2002, 346:126-128.
4. Ramalingam S., Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008, 13(Suppl. 1):5-13.
5. Cox G., Walker R.A., Andi A., Steward W.P., O'Byrne K.J. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 2000, 29:169-177.
6. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
7. Herbst R.S., Onn A., Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J. Clin. Oncol. 2005, 23:3243-3256.
8. Fontanini G., Boldrini L., Chine S., Pisaturo F., Basolo F., Calcinai A., Lucchi M., Mussi A., Angeletti C.A., Bevilacqua G. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br. J. Cancer 1999, 79:363-369.
9. Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Tamaoki N., Ueyama Y. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int. J. Oncol. 1998, 12:541-544.
10. Giatromanolaki A., Koukourakis M.I., Kakolyris S., Turley H., O'Byrne K., Scott P.A., Pezzella F., Georgoulias V., Harris A.L., Gatter K.C. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 1998, 4:3017-3024.
11. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., Cox G., Turley H., Steward W.P., Gatter K., Harris A.L. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer 2000, 82:1427-1432.
12. Hinz B., Brune K. Cyclooxygenase-2-10years later. J. Pharmacol. Exp. Ther. 2002, 300:367-375.
13. Needleman P., Isakson P.C. Selective inhibition of cyclooxygenase-2. Sci. Med. 1998, 26-35.
14. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Holscher A.H., Danenberg K.D., Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg. 2002, 235:440-443.
15. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7:861-867.
16. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 1999, 5:1001-1005.
17. Edelman M.J., Watson D., Wang X., Morrison C., Kratzke R.A., Jewell S., Hodgson L., Mauer A.M., Gajra A., Masters G.A., Bedor M., Vokes E.E., Green M.J. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy-cancer and leukemia group B Trial 30203. J. Clin. Oncol. 2008, 26:848-855.
18. Fidler M.J., Argiris A., Patel J.D., Johnson D.H., Sandler A., Villaflor V.M., Coon J.t., Buckingham L., Kaiser K., Basu S., Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin. Cancer Res. 2008, 14:2088-2094.
19. Mutter R., Lu B., Carbone D.P., Csiki I., Moretti L., Johnson D.H., Morrow J.D., Sandler A.B., Shyr Y., Ye F., Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin. Cancer Res. 2009, 15:2158-2165.
20. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 2000, 343:1520-1528. (1522 p following 1528).
21. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352:1092-1102.
22. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
23. Brown J.R., DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin. Cancer Res. 2004, 10:4266s-4269s.
24. Haurand M., Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J. Biol. Chem. 1985, 260:15059-15067.
25. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
26. Samuelsson B., Goldyne M., Granstrom E., Hamberg M., Hammarstrom S., Malmsten C. Prostaglandins and thromboxanes. Annu. Rev. Biochem. 1978, 47:997-1029.
27. Kajita S., Ruebel K.H., Casey M.B., Nakamura N., Lloyd R.V. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod. Pathol. 2005, 18:221-227.
28. Moussa O., Yordy J.S., Abol-Enein H., Sinha D., Bissada N.K., Halushka P.V., Ghoneim M.A., Watson D.K. Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res. 2005, 65:11581-11587.
29. Nie D., Che M., Zacharek A., Qiao Y., Li L., Li X., Lamberti M., Tang K., Cai Y., Guo Y., Grignon D., Honn K.V. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am. J. Pathol. 2004, 164:429-439.
30. Nie D., Lamberti M., Zacharek A., Li L., Szekeres K., Tang K., Chen Y., Honn K.V. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. 2000, 267:245-251.
31. Sakai H., Suzuki T., Takahashi Y., Ukai M., Tauchi K., Fujii T., Horikawa N., Minamimura T., Tabuchi Y., Morii M., Tsukada K., Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett. 2006, 580:3368-3374.
32. Dassesse T., de Leval X., de Leval L., Pirotte B., Castronovo V., Waltregny D. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur. Urol. 2006, 50:1021-1031. (discussion 1031).
33. Cathcart M.C., Gately K., Cummins R., Kay E., KJ O.B., Pidgeon G.P. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol. Cancer 2011, 10:25.
34. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59:4574-4577.
35. Pradono P., Tazawa R., Maemondo M., Tanaka M., Usui K., Saijo Y., Hagiwara K., Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002, 62:63-66.
36. Arisato T., Hashiguchi T., Sarker K.P., Arimura K., Asano M., Matsuo K., Osame M., Maruyama I. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J. Thromb. Haemost. 2003, 1:2589-2593.
37. Rhee J.S., Black M., Schubert U., Fischer S., Morgenstern E., Hammes H.P., Preissner K.T. The functional role of blood platelet components in angiogenesis. Thromb. Haemost. 2004, 92:394-402.
38. Mao X.Y., Wang X.G., Lv X.J., Xu L., Han C.B. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J. Gastroenterol. 2007, 13:3466-3471.
39. Zhan P., Wang J., Lv X.J., Wang Q., Qiu L.X., Lin X.Q., Yu L.K., Song Y. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J. Thorac. Oncol. 2009, 4:1094-1103.
40. Donnem T., Al-Saad S., Al-Shibli K., Delghandi M.P., Persson M., Nilsen M.N., Busund L.T., Bremnes R.M. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer. Clin. Cancer Res. 2007, 13:6649-6657.
41. Sheehan K.M., Steele C., Sheahan K., O'Grady A., Leader M.B., Murray F.E., Kay E.W. Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer. Histopathology 2005, 46:287-295.
42. Wei J., Yan W., Li X., Ding Y., Tai H.H. Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer 2010, 69:26-32.
43. Yoshimoto A., Kasahara K., Kawashima A., Fujimura M., Nakao S. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol. Rep. 2005, 13:1049-1057.
44. Ermert L., Dierkes C., Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res. 2003, 9:1604-1610.
45. Jantke J., Ladehoff M., Kurzel F., Zapf S., Kim E., Giese A. Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir. (Wien) 2004, 146:483-494.
46. Blom J.W., Osanto S., Rosendaal F.R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J. Thromb. Haemost. 2004, 2:1760-1765.
47. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., Hirasawa M., Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 1999, 160:1269-1273.
48. Pajares M.J., Agorreta J., Larrayoz M., Vesin A., Ezponda T., Zudaire I., Torre W., Lozano M.D., Brambilla E., Brambilla C., Wistuba I.I., Behrens C., Timsit J.F., Pio R., Field J.K., Montuenga L.M. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J. Clin. Oncol. 2012, 30:1129-1136.
49. Li M., Kuo L., Stallone J.N. Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2444-H2455.
50. Watkins G., Douglas-Jones A., Mansel R.E., Jiang W.G. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int. Semin. Surg. Oncol. 2005, 2:23.
51. Huang R.Y., Li M.Y., Hsin M.K., Underwood M.J., Ma L.T., Mok T.S., Warner T.D., Chen G.G. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene 2011, 30:106-116.
52. Huang R.Y., Li M.Y., Ng C.S., Wan I.Y., Kong A.W., Du J., Long X., Underwood M.J., Mok T.S., Chen G.G. Thromboxane A2 receptor alpha promotes tumor growth through an autoregulatory feedback pathway. J. Mol. Cell Biol. 2013, 5:380-390.
53. Moussa O., Ashton A.W., Fraig M., Garrett-Mayer E., Ghoneim M.A., Halushka P.V., Watson D.K. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res. 2008, 68:4097-4104.
54. Leung K.C., Li M.Y., Leung B.C., Hsin M.K., Mok T.S., Underwood M.J., Chen G.G. Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB. Exp. Cell Res. 2010, 316:3468-3477.
55. Ekambaram P., Lambiv W., Cazzolli R., Ashton A.W., Honn K.V. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev. 2011, 30:397-408.
56. Verheul H.M., van Erp K., Homs M.Y., Yoon G.S., van der Groep P., Rogers C., Hansel D.E., Netto G.J., Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010, 75:608-614.
57. Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., Stroiakovski D., Thatcher N., Tsai C.M., Wu Y.L., Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010, 11:733-740.
58. Hang X.F., Xu W.S., Wang J.X., Wang L., Xin H.G., Zhang R.Q., Ni W. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 2011, 67:613-623.
59. Leighl N.B., Bennouna J., Yi J., Moore N., Hambleton J., Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br. J. Cancer 2011, 104:413-418.
60. Yang X.R., Xu Y., Yu B., Zhou J., Qiu S.J., Shi G.M., Zhang B.H., Wu W.Z., Shi Y.H., Wu B., Yang G.H., Ji Y., Fan J. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010, 59:953-962.